JPS61116346A - Silver halide photosensitive material - Google Patents
Silver halide photosensitive materialInfo
- Publication number
- JPS61116346A JPS61116346A JP23713484A JP23713484A JPS61116346A JP S61116346 A JPS61116346 A JP S61116346A JP 23713484 A JP23713484 A JP 23713484A JP 23713484 A JP23713484 A JP 23713484A JP S61116346 A JPS61116346 A JP S61116346A
- Authority
- JP
- Japan
- Prior art keywords
- group
- silver halide
- substituted
- formula
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 36
- -1 Silver halide Chemical class 0.000 title claims description 71
- 229910052709 silver Inorganic materials 0.000 title claims description 51
- 239000004332 silver Substances 0.000 title claims description 51
- 239000000839 emulsion Substances 0.000 claims abstract description 62
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 20
- 150000001450 anions Chemical class 0.000 claims abstract description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 5
- 125000004429 atom Chemical group 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 150000001875 compounds Chemical group 0.000 claims description 29
- 230000003287 optical effect Effects 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 10
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 9
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000000758 substrate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 38
- 239000002245 particle Substances 0.000 description 31
- 238000000586 desensitisation Methods 0.000 description 21
- 206010070834 Sensitisation Diseases 0.000 description 19
- 239000013078 crystal Substances 0.000 description 18
- 230000008313 sensitization Effects 0.000 description 18
- 238000012545 processing Methods 0.000 description 17
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 12
- 229910021612 Silver iodide Inorganic materials 0.000 description 12
- 229940045105 silver iodide Drugs 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 5
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 230000001235 sensitizing effect Effects 0.000 description 4
- ZUNKMNLKJXRCDM-UHFFFAOYSA-N silver bromoiodide Chemical compound [Ag].IBr ZUNKMNLKJXRCDM-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001555 benzenes Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000011258 core-shell material Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XEIPQVVAVOUIOP-UHFFFAOYSA-N [Au]=S Chemical compound [Au]=S XEIPQVVAVOUIOP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000006224 matting agent Substances 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- HAAYBYDROVFKPU-UHFFFAOYSA-N silver;azane;nitrate Chemical compound N.N.[Ag+].[O-][N+]([O-])=O HAAYBYDROVFKPU-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- LUMLZKVIXLWTCI-NSCUHMNNSA-N (e)-2,3-dichloro-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Cl)=C(/Cl)C=O LUMLZKVIXLWTCI-NSCUHMNNSA-N 0.000 description 1
- GGZHVNZHFYCSEV-UHFFFAOYSA-N 1-Phenyl-5-mercaptotetrazole Chemical compound SC1=NN=NN1C1=CC=CC=C1 GGZHVNZHFYCSEV-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229910003803 Gold(III) chloride Inorganic materials 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- SJOOOZPMQAWAOP-UHFFFAOYSA-N [Ag].BrCl Chemical compound [Ag].BrCl SJOOOZPMQAWAOP-UHFFFAOYSA-N 0.000 description 1
- XCFIVNQHHFZRNR-UHFFFAOYSA-N [Ag].Cl[IH]Br Chemical compound [Ag].Cl[IH]Br XCFIVNQHHFZRNR-UHFFFAOYSA-N 0.000 description 1
- POXQYTSDKNMATI-UHFFFAOYSA-N [N+](=S)([O-])[O-].[Na+] Chemical compound [N+](=S)([O-])[O-].[Na+] POXQYTSDKNMATI-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- RJHLTVSLYWWTEF-UHFFFAOYSA-K gold trichloride Chemical compound Cl[Au](Cl)Cl RJHLTVSLYWWTEF-UHFFFAOYSA-K 0.000 description 1
- 229940076131 gold trichloride Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910001504 inorganic chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002503 iridium Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- ZAKLKBFCSHJIRI-UHFFFAOYSA-N mucochloric acid Natural products OC1OC(=O)C(Cl)=C1Cl ZAKLKBFCSHJIRI-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- AYKOTYRPPUMHMT-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag] AYKOTYRPPUMHMT-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C1/00—Photosensitive materials
- G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
- G03C1/035—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein characterised by the crystal form or composition, e.g. mixed grain
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C1/00—Photosensitive materials
- G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
- G03C1/035—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein characterised by the crystal form or composition, e.g. mixed grain
- G03C2001/03535—Core-shell grains
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C1/00—Photosensitive materials
- G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
- G03C1/035—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein characterised by the crystal form or composition, e.g. mixed grain
- G03C2001/03564—Mixed grains or mixture of emulsions
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C5/00—Photographic processes or agents therefor; Regeneration of such processing agents
- G03C5/16—X-ray, infrared, or ultraviolet ray processes
- G03C2005/168—X-ray material or process
Landscapes
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Abstract
Description
【発明の詳細な説明】
〔発明の利用分野〕
本発明はX線用ハロゲン化銀写真感光材料に関する。こ
の種の感光材料は医療分野において各種診断のために使
用されるほか、産業分野でX線深傷技術等の一環として
用いられ、更に生体工学等の分野で放射性同位体元素の
追跡などのために使用されるなど、広く利用されている
。DETAILED DESCRIPTION OF THE INVENTION [Field of Application of the Invention] The present invention relates to a silver halide photographic material for X-rays. This type of photosensitive material is used for various diagnostic purposes in the medical field, as part of X-ray deep wound technology in the industrial field, and for tracing radioactive isotopes in fields such as bioengineering. It is widely used.
X線用ハロゲン化銀写真感光材料(支持体の両面に感光
性乳剤層を有するものと、片面のみに感光性乳剤層を有
するものとがあるが、以下、両者を含めて単に「X線感
材」と称する。)は、鮮鋭度が高く、情報量が多く、か
つ粒状性が良く、圧力減感(つまシ圧力による減感)も
しに<<、また画質の劣化が少ないことが要求される。X-ray silver halide photographic light-sensitive materials (some have a photosensitive emulsion layer on both sides of the support and others have a photosensitive emulsion layer on only one side; hereinafter, both types will be referred to simply as "X-ray sensitive"). ) is required to have high sharpness, large amount of information, good graininess, resistance to pressure desensitization (desensitization due to tab pressure), and little deterioration of image quality. Ru.
例えば医療用X線感材について言えば、鮮鋭度が高く、
粒状性が良い程診断し易いし、情報量が多い程診断能が
高いので有利で6)、かつ圧力減感が少なくて情報が確
実に画像化され、しかも画質が劣化せずに保存性の良い
ことが望まれる。For example, regarding medical X-ray sensitive materials, they have high sharpness,
The better the granularity, the easier it is to diagnose, and the greater the amount of information, the higher the diagnostic ability, which is advantageous6).In addition, there is less pressure desensitization, information is reliably visualized, and the image quality does not deteriorate and storage stability is improved. Good things are desired.
このように医療分野での生体各部位のX線写真撮影にお
いては、病巣の早期発見および誤診の防止のためにも、
画偉が鮮鋭で6って、情報量も多く、診断能の高いこと
が求められるが、従来のX線感材は未だ必ずしも満足で
きるものではない。In this way, when taking X-ray photographs of various parts of the body in the medical field, in order to detect lesions early and prevent misdiagnosis,
It is required that the image quality be sharp, that is, 6, that there is a large amount of information, and that the diagnostic ability is high, but conventional X-ray sensitive materials are still not always satisfactory.
即ち、従来の直接用X線感材は、第1図の特性曲線にお
いて(&)で示す高ガンマ型、Φ)で示す低ガンマ型、
(C)で示す中庸型に大別される。しかし高ガンマ型(
&)は、図の如く特性曲線の立ち上がりが急なので鮮鋭
度は高いが、低露光量部の情報量に乏しい。逆に低ガン
マ型(b)は、線量f:il1節して図の左側に曲線を
平行移動した(b′)の形で便用でき、この場合低露光
域での写真濃度りを上げられるので低露光量部の情報量
は豊富だが、特性曲線の傾きが緩くて鮮鋭度が低い為に
診断しにくい。また中庸タイプ(e)は、鮮鋭度も低濃
度部の情報量も中程度に過ぎない。That is, in the characteristic curve of FIG. 1, the conventional direct X-ray sensitive material has a high gamma type indicated by (&), a low gamma type indicated by Φ),
It is broadly classified into the moderate type shown in (C). However, high gamma type (
&) has a high sharpness because the characteristic curve rises steeply as shown in the figure, but the amount of information in the low exposure portion is poor. On the other hand, the low gamma type (b) can be conveniently used in the form of (b') in which the dose is f: il1 and the curve is moved in parallel to the left side of the figure, and in this case, the photographic density in the low exposure area can be increased. Therefore, the amount of information in the low exposure area is rich, but the slope of the characteristic curve is gentle and the sharpness is low, making diagnosis difficult. Furthermore, the medium type (e) has only a medium sharpness and a medium amount of information in low density areas.
“これら各タイプの直接用X線感材について、その各濃
度におけるガンマは、代表的には次の表−1に示すよう
になる。なお同表に示す各ガンマは、光学濃度(ロ)及
び露光量(log E)の座標軸単位長の等しい直角座
標系上の特性曲線に於て、光学濃度0.050点と同0
.30の点の作るガンマをガン11(it)とし、光学
濃度0.500点と同1.500点の作るガンマをガ/
72 (r2)とし、光学濃度2.00と同3.00と
の間のガンマをガン−f3(γ5)としたものである。“For each type of direct X-ray sensitive material, the gamma at each density is typically as shown in Table 1 below. Each gamma shown in the table is based on the optical density (b) and In a characteristic curve on a rectangular coordinate system with the same unit length of the coordinate axes of exposure (log E), the optical density is the same as 0.050 point.
.. Let the gamma created by the 30 points be Gan 11 (it), and the gamma created by the optical density 0.500 point and the same 1.500 point be Ga/
72 (r2), and the gamma between the optical density of 2.00 and 3.00 is defined as gamma-f3 (γ5).
表−1
ところがこれら従来タイプの直接用X線感材によるX線
写真撮影の実際例においては、次のような大きな問題が
生じている。即ち、我が国でxls写真撮影の最も多い
生体部位は胸部、胃及び手足の骨りようであるが、上記
従来のX線感材では、各部位すべてた対しては、必ずし
も十分に満足の行く撮影は達成されていないのである。Table 1 However, in actual examples of X-ray photography using these conventional type direct X-ray sensitive materials, the following major problems occur. In other words, the body parts most commonly photographed using XLS in Japan are the chest, stomach, and bones of the limbs, but with the conventional X-ray sensitive materials mentioned above, it is not always possible to obtain satisfactory images for all of these parts. has not been achieved.
まず胸部であるが、胸部写真の読影で重要な部位は肺野
部の血管及び心臓の裏にある冠動脈である。First of all, regarding the chest, the important parts when interpreting a chest photograph are the blood vessels in the lung area and the coronary arteries behind the heart.
肺野部は中庸濃度領域(O=t、a〜1.5)であり、
その中の血管を読影する為には高い鮮鋭度が要求され、
同時に冠動脈は低濃度領域(D=0.05〜0.30)
におるので広いラチチュードが要求される。つまυ露光
許容度が広くて十分な情報を画像として得られることが
要求される。しかし従来の高ガンマ型X線感材では、肺
野部の鮮鋭度は高いが、冠動脈は非常に低い濃度でしか
描写されず、実質上、診断に寄与できなかった。逆に低
ガンマ型X線感材を用いた場合では、冠動脈は描写され
るが肺野部の鮮鋭度は低かった。The lung field is in the moderate concentration region (O = t, a ~ 1.5),
High sharpness is required to interpret the blood vessels inside.
At the same time, the coronary artery is a low concentration area (D = 0.05-0.30)
A wide latitude is required. Finally, it is required that the exposure latitude is wide and sufficient information can be obtained as an image. However, with conventional high-gamma X-ray sensitive materials, although the lung field has high sharpness, the coronary arteries are depicted only at very low density, and cannot substantially contribute to diagnosis. Conversely, when a low gamma type X-ray sensitive material was used, the coronary arteries were depicted, but the sharpness of the lung field was low.
次に胃のX線撮影であるが、この撮影においては描写力
を高めるために造影剤が用いられるので、従来の高ガン
マ型直接用X#I感材では、造影剤の部分に露光量を合
わせた場合、造影剤の無い部分は現像後真黒につぶれた
像しか得られず、何ら診断に寄与できなかった。このよ
うな現象を避けるために低ガンi型直接用X線感材が用
いられることが多いが、このX線感材の場合は、反面、
鮮鋭度が低下するために造影剤を含んだ胃壁部位の診断
能が低減してしまう。Next is X-ray photography of the stomach, but since a contrast agent is used to enhance the descriptive power in this X-ray photography, conventional high-gamma type X#I photosensitive materials for direct use reduce the amount of exposure to the contrast agent area. When combined, only a completely black image was obtained after development of the area without the contrast agent, which could not contribute to diagnosis in any way. In order to avoid this phenomenon, low-gamma-type direct X-ray sensitive materials are often used; however, in the case of this X-ray sensitive material,
Since the sharpness decreases, the diagnostic ability of the gastric wall region containing the contrast agent decreases.
次に手や脚などの骨りよう及び軟部組織(内部ないし軟
骨部)の撮影この場合においても、従来の高ガンマ型X
線感材では骨シようの微細構造の鮮鋭度は高いが、軟部
組織は真黒につぶれてしまい、診断に寄与できなかった
。逆に、低ガンマ型X線感材を用いた場合では、軟部組
織は描写されるが骨りようの鮮鋭度が低かった。Next, imaging of bone tissue and soft tissue (internal or cartilage) of hands and legs, etc. In this case, conventional high-gamma X
Although the fine structure of bone scars was highly sharp with the line-sensitive material, the soft tissue was crushed to a pitch black color and could not contribute to diagnosis. Conversely, when a low gamma type X-ray sensitive material was used, soft tissue was depicted, but the sharpness of bone tissue was low.
また各種感光材料においては、露光前に加わる種々の機
械的圧力によシ圧力減感(露光前の機械的圧力が原因で
現像時に認められる減感)が生ずることがらシ、X線感
材においてもこの問題がある。特に医療用Xレイフィル
ムはフィルムサイズが大きいため、支えた部分から自重
で折れ曲がるなどの現象、いわゆるつめ折れなどのフィ
ルム折れ曲がりが生ずることがあり、これ罠より、圧力
減感が生じやすい。また、昨今、医療用Xレイ写真シス
テムとして、機械搬送を用いた自動露光および現像装置
がひろく使用されているが、こうした装置中では機械的
な力がフィルムにかかフ、特に冬期など乾燥したところ
では、前記の圧力黒化と圧力減感とが発生しやすい。そ
して、このような現象は、医療診断において重大な支障
をきたしてしまうおそれがある。In addition, in various photosensitive materials, pressure desensitization (desensitization observed during development due to mechanical pressure before exposure) may occur due to various mechanical pressures applied before exposure. also has this problem. In particular, medical X-ray film is large in size, so it may bend under its own weight from the supported part, or the film may bend, such as so-called claw folding, which is more likely to cause pressure desensitization. In addition, automatic exposure and developing devices using mechanical conveyance are now widely used as medical X-ray photography systems, but in these devices, mechanical force is applied to the film, especially when it is dry during the winter. However, the aforementioned pressure blackening and pressure desensitization are likely to occur. Such a phenomenon may cause serious problems in medical diagnosis.
特に、粒径の大きい高感度のノ・ロゲン化銀粒子を有す
る写真感光材料はど、圧力減感が生じやすいことはよく
知られている。It is well known that pressure desensitization is particularly likely to occur in photographic materials containing highly sensitive silver halide grains with large grain sizes.
圧力減感に対する改良を目的としたものとして米国特許
2,628,167号、同2,759,822号、同3
,445,235号、同2,296,204号およびフ
ランス特許2,296,204号、特開昭51−107
129号および同50−116025号等に例えばタリ
ウムを用いるものや色素を用いるものが記載されている
が、その程度の改良は不充分であったり、また色素汚染
がはなはだしく、また他のものは必ずしもハロゲノ化釧
粒子の平均粒径の大きい高感度の通常の表面感度を主に
利用したハロゲン化銀感光材料の資質を充分に引出した
ものとはいい難い。US Pat. Nos. 2,628,167, 2,759,822, and 3 are aimed at improving pressure desensitization.
, No. 445,235, No. 2,296,204 and French Patent No. 2,296,204, Japanese Patent Application Laid-Open No. 1983-107
No. 129 and No. 50-116025, etc., describe methods using thallium or dyes, but the degree of improvement is insufficient, dye staining is severe, and other methods are not always suitable. It cannot be said that this material fully brings out the qualities of a silver halide photosensitive material that mainly utilizes the high sensitivity and normal surface sensitivity of the halide grains having a large average particle size.
一方、ハロゲン化銀写真感光材料のバインダー物性を変
える事による圧力減感の改良が種々試みられている。例
えば米国特許3,536,491号、同3,775,1
28号、同3,003,878号、同2゜759.82
1号および同3,772,032号、更に特開昭53−
3325号、同50−56227号、同50−1473
24号および同51−141625号等に記載されてい
る。しかしながら、これらの技術は圧力減感が改良され
ても、フィルム表面のベタつきや乾燥性、擦傷などのバ
インダー物性等の劣化が著しく根本的には改良しえない
。On the other hand, various attempts have been made to improve pressure desensitization by changing the physical properties of the binder of silver halide photographic materials. For example, U.S. Patent Nos. 3,536,491 and 3,775,1
No. 28, No. 3,003,878, No. 2゜759.82
No. 1 and No. 3,772,032, as well as JP-A-53-
No. 3325, No. 50-56227, No. 50-1473
No. 24 and No. 51-141625. However, even if these techniques improve pressure desensitization, the physical properties of the binder such as stickiness, dryness, and scratches on the film surface are significantly deteriorated and cannot be fundamentally improved.
一方近年、写真技術の発達にともない、ハロゲン化銀写
真感光材料の高感度化が強く望まれており、医療用Xレ
イ写真の分野でも従来450 nmに感1光波長域があ
ったレギュラータイプから、更にオルソ増感して、54
0〜550 nmの波長域で感光するオルソタイプの感
光材料が用いられるようになっている。このように増感
されたものは、感光波長域が広くなるとともに感度が高
くなってお9、従って、被曝X線量を低減でき、人体等
に与える影響を小さくできる。On the other hand, in recent years, with the development of photographic technology, there has been a strong desire for higher sensitivity of silver halide photographic materials, and in the field of medical X-ray photography, there has been a shift from the regular type, which had a sensitivity of 1 wavelength at 450 nm, to , further ortho-sensitized, 54
Orthotype photosensitive materials that are sensitive to a wavelength range of 0 to 550 nm have come into use. Those sensitized in this way have a wider photosensitive wavelength range and a higher sensitivity9, and therefore can reduce the amount of X-rays that they are exposed to and the effect they have on the human body.
従って、例えば上記の如き増感手段によシ感度を高める
ことができるとともに、前記したようなどの部位に対し
ても良好な影像を得ることができ、かつ圧力減感が改良
されたX線感材の開発が望まれているのが現状である。Therefore, for example, the sensitivity can be increased by the above-mentioned sensitizing means, and good images can be obtained even for the above-mentioned areas, and the X-ray sensitivity is improved in pressure desensitization. Currently, there is a need for the development of new materials.
〔発明の目的]
本発明の目的は、高鮮鋭度で、かつ低濃度部及び高濃度
部の露光ラチチュードが広く、よって医療用に用いる場
合には診断能を高めることができ、しかも粒状性が良く
、圧力減感もしに<<、画質の劣化も少ない、有利なX
線感材を提供することである。[Objective of the Invention] The object of the present invention is to provide high sharpness and wide exposure latitude in low-density areas and high-density areas, thereby improving diagnostic ability when used for medical purposes, and reducing graininess. Good, pressure desensitization <<, less deterioration of image quality, advantageous X
The purpose of the present invention is to provide line-sensitive materials.
家廃明に係るX線感材は、光学濃度ρ)及び露光量(l
og B)の座標軸単位長の等しい直角座標系上の特性
曲線に於て、光学濃度0.05の点と同0.30の点の
作るガフff(r+)が0.36〜0.65であり、か
つ光学濃度0.500点と同i、soの点の作るガンマ
(γ2)が2.7〜3.3であシ、かつ光学濃度2.O
Oと同3.OOとの間のガンマ(γ5)が1.5〜2.
5であることを特徴とする。The X-ray sensitive material related to house ruins has an optical density ρ) and an exposure amount (l
In the characteristic curve on the rectangular coordinate system with the same coordinate axis unit length of og B), the gaff ff(r+) created by the point of optical density 0.05 and the point of optical density 0.30 is 0.36 to 0.65. , and the gamma (γ2) created by the points i and so, which are the same as the optical density 0.500 point, is 2.7 to 3.3, and the optical density is 2. O
Same as O 3. Gamma (γ5) between OO and OO is 1.5 to 2.
It is characterized by being 5.
この構成をとることによシ、本発明のX線感材は、上述
した目的を達成できる。本発明においては、これら各構
成が相俟って上記目的を達成するわけであるが、大ざっ
ばに言えば、rlを上記範囲にすることによシ低濃度部
の露光ラチチュードを広くでき、12を上記範囲にする
ことにより鮮鋏性を高め、r5を上記範囲にすることに
より高濃度部の露光ラチチュードを広くできたものと言
うことができる。またこの構成により、粒状性の改善、
圧力減圧の防止、画質劣化の防止が達成される。By adopting this configuration, the X-ray sensitive material of the present invention can achieve the above-mentioned object. In the present invention, each of these configurations works together to achieve the above object, but roughly speaking, by setting rl in the above range, the exposure latitude in the low density area can be widened. It can be said that by setting 12 in the above range, the sharpness is improved, and by setting r5 in the above range, the exposure latitude in the high density area can be widened. This configuration also improves graininess and
Prevention of pressure reduction and image quality deterioration is achieved.
本発明の実施に際しては、好ましくは下記処理条件によ
って処理された時の前記直角座標系上の特性曲線に於て
前記rlが0.36〜0.65であシ、γ2が2.7〜
3.3であり、r5が1.5〜2.5である特性曲線が
えられるようにする。When carrying out the present invention, preferably, in the characteristic curve on the rectangular coordinate system when processed under the following processing conditions, the rl is 0.36 to 0.65, and γ2 is 2.7 to 2.7.
3.3, and a characteristic curve with r5 of 1.5 to 2.5 is obtained.
下記現像液−1を用いて、下記の工程に従い、ローラー
搬送型自動現像機で処理する。Processing is carried out using a roller conveyance type automatic developing machine according to the following steps using the following developer solution-1.
処理温度 処理時間
現像液−1
但し、上記条件中、処理温度や処理時間、及び現像主薬
の量など、多少幅がおってもよい。Processing temperature Processing time Developer-1 However, among the above conditions, the processing temperature, processing time, amount of developing agent, etc. may vary somewhat.
本発明でいう特性曲線は、例えば次のような光センシト
メトリーCAIによって得られるものである。即ちこの
光センシトメトリーCAIにおいては、露光は、透明性
支持体の両面(又は片面)に感光性乳剤層を有するX線
感材を濃度傾斜を鏡対称に整合した2枚の光学ウェッジ
に挾み、色温度5.400’にの光源で両側から同時に
かつ等量、1/10秒間露光する。処理は、前記の工程
に従い、ローラー搬送型の自動現像機を用いて行なう。The characteristic curve referred to in the present invention is obtained by, for example, the following optical sensitometry CAI. That is, in this photosensitometric CAI, exposure is carried out by sandwiching an X-ray sensitive material having a photosensitive emulsion layer on both sides (or one side) of a transparent support between two optical wedges whose density gradients are mirror-symmetrically aligned. and then exposed to a light source with a color temperature of 5.400' for 1/10 seconds from both sides simultaneously and equally. The processing is carried out using a roller conveyance type automatic developing machine according to the above-mentioned steps.
定着液は酸性硬膜定着液であれば特に制限はなく、例え
ばサクラXF(小西六写真工業製)などである@
本発明でいうガンマは、光学濃度(D)及び露光量対数
(log E)の座標軸単位長を等しくとった直角座標
系上で作図された特性曲線に拠って求められる。前記γ
1は該特性曲線上のベース(支持体)濃度子カプリ濃度
+0.05の濃度の点と、ベース濃度子カプリ濃度+0
.30の濃度の点を結んだ直線の傾きを意味し、また前
記r2はベース濃度子カプリ濃度子0.500濃度の点
と、ベース濃度子カプリ濃度+1.500濃度の点を結
んだ直線の傾きを意味し、また前記r5はペース濃度子
カプリ濃度+2.00の濃度の点と、ペース濃度子カプ
リ濃度+3.00の濃度の点を結んだ直線の傾きを意味
する。更に数値的に表現すれば、これらの直線が露光量
軸(横軸)と交わる角度を01.θ2及びθ)とすれば
、rl及びγ2は夫々tanθ1 、 tJLnθ2及
びtLnθう を意味する。The fixer is not particularly limited as long as it is an acidic hardening fixer, such as Sakura It is determined based on a characteristic curve plotted on a rectangular coordinate system in which the unit length of the coordinate axes is set equal. Said γ
1 is the density point on the characteristic curve of the base (support) concentration factor Capri density + 0.05 and the point of the base concentration factor Capri density + 0.
.. r2 means the slope of the straight line connecting the points with a density of 30, and the above r2 is the slope of the straight line connecting the point with a base density of Capri density of 0.500 and the point of the base density with Capri density + 1.500 density. In addition, r5 means the slope of the straight line connecting the point at the density of pace concentration sub-capri density +2.00 and the point at the density of pace density sub-capri density +3.00. To further express it numerically, the angle at which these straight lines intersect with the exposure axis (horizontal axis) is 01. θ2 and θ), rl and γ2 mean tanθ1, tJLnθ2 and tLnθ, respectively.
本発明の特性曲線を得る方法は任意であシ、単分散乳剤
、多分散乳剤、コア・シェル型単分散乳剤、コア・シェ
ル型多分散乳剤の単用ないし2以上の組合せ利用、粒径
ないし粒度分布のコントロール、ハロゲン化銀晶癖の最
適化、硬膜度の調整、現像促進剤の添加、現像抑制剤の
添加などいずれの技術によってもよい。The method of obtaining the characteristic curve of the present invention is arbitrary, and may include the use of monodisperse emulsions, polydisperse emulsions, core-shell type monodisperse emulsions, core-shell type polydisperse emulsions alone or in combination of two or more, particle size or Any technique such as controlling the particle size distribution, optimizing the silver halide crystal habit, adjusting the hardness, adding a development accelerator, or adding a development inhibitor may be used.
本発明の好ましい実施態様にあっては、上記任意の手段
により得九粒子を、次に示す一般式(I)CIII及び
唾〕で表わされる化合物群から選ばれた少なくとも1種
類の化合物を用いて色素増感することにより、本発明の
上記特性曲線を得る。この場合、好ましくは2種以上の
単分散粒子または多分散粒子の併用によって、これを達
成する。fた、これら粒子に化学増感を施すこともでき
、その場合には、それぞれ別々に最適な化学増感を行っ
てもよいし、両者を混合後、化学増感してもよい。In a preferred embodiment of the present invention, nine particles obtained by any of the above-mentioned methods are obtained by using at least one compound selected from the group of compounds represented by the following general formula (I) CIII and saliva. The above characteristic curve of the present invention is obtained by dye sensitization. In this case, this is preferably achieved by a combination of two or more types of monodisperse particles or polydisperse particles. Alternatively, these particles may be chemically sensitized; in that case, the optimum chemical sensitization may be performed separately for each particle, or the two may be mixed and then chemically sensitized.
本発明の実施については、どちらかというと、前者が好
ましい。For implementation of the present invention, the former is rather preferred.
このように一般式CI〕(III [1の化合物のいず
れかを用いる態様を採用すると、オルソ増感されるので
、特に粒状性及び圧力減感について、一層の改良がなさ
れる。即ち、レギュラータイプでは高感度を要する脚部
用に大粒子を用いていたため、粒状性及び圧力減感性能
が悪かったのであるが、このようなオルソタイプでは色
素増感により高感度化されるため、用いるハロゲン化銀
粒子を小さくすることができる。この結果、粒状性及び
圧力減感性能を一層改良することができるわけである。In this way, if an embodiment using any of the compounds of the general formula CI](III [1) is adopted, ortho-sensitization is carried out, and further improvements are made particularly in terms of graininess and pressure desensitization. In other words, regular type Because large particles were used for the legs, which required high sensitivity, the graininess and pressure desensitization performance were poor.However, in such orthotypes, the sensitivity is increased by dye sensitization, so the halogenation used is Silver particles can be made smaller. As a result, graininess and pressure desensitization performance can be further improved.
一般式CI) ([1(I[I]は次に示す通りである
。General formula CI) ([1(I[I] is as shown below.
一般式
%式%)
〔式中、”1 、R2,Rうは各々置換もしくは非置換
のアルキル基、アルケニル基またはアリール基を表わし
、少なくともR1とRうの内1つはスルホアルキル基ま
たはカルボキシアルキル基ヲトる。Xiはアニオン、z
lおよびz2は置換または非置換のベンゼン環を完成す
るに必要な非金属原子群、nは1または2を表わす。(
ただし、分子内塩を形成するときはnはlである。)〕
〔■〕
(X;)n−0
〔式中、R,、R,は各々置換もしくは非置換のアルキ
ル基、アルケニル基またはアリール基を表わし、少なく
ともR4とR5の内いずれかはスルホアルキル基または
カルボキシアルキル基をとる。R6は水素原子、低難ア
ル中ル基、了り−ル基を表わす。[General formula % formula %] [In the formula, "1", R2, and R each represent a substituted or unsubstituted alkyl group, alkenyl group, or aryl group, and at least one of R1 and R is a sulfoalkyl group or a carboxy Alkyl group is used. Xi is an anion, z
1 and z2 represent a group of nonmetallic atoms necessary to complete a substituted or unsubstituted benzene ring, and n represents 1 or 2. (
However, when forming an inner salt, n is l. )] [■] (X;)n-0 [In the formula, R,, R, each represents a substituted or unsubstituted alkyl group, alkenyl group, or aryl group, and at least one of R4 and R5 is sulfoalkyl or carboxyalkyl group. R6 represents a hydrogen atom, a low alkali group, or an alkyl group.
Xiはアニオン、2□およびz2杖置換または非置換の
ベンゼン環を完成するに必要な非金属原子群、nは1ま
たは2t−表わす。(ただし、分子内塩を形成するとき
はnは1である。)〕
aD
(Xl)n−1
〔式中、R7およびR9は各々置換もしくは非置換の低
級アルキル基、RgおよびRIOは低級アルキル基、ヒ
ドロキシアルキル基、スルホアルキル基、カルボキシア
ルキル基、Xlはアニオン、zl およびz2は置換ま
たは非置換のベンゼン環を完成するに必要な非金属原子
群、nは1または2を表わす。(ただし、分子内塩を形
成するときはれはlである。)〕
本発明のX線感材を形成する乳剤に一般式〔工〕CII
) (III)の化合物を用いる場合、そのハロゲン化
銀乳剤中に含まれるハロゲン化銀粒子の重量又は粒子数
は、少なくともその95%が平均粒子径の±4C1以内
の粒子径を有することが好ましい。Xi represents an anion, 2□ and a group of nonmetallic atoms necessary to complete the z2-rod-substituted or unsubstituted benzene ring, and n represents 1 or 2t-. (However, when forming an inner salt, n is 1.)] aD (Xl)n-1 [In the formula, R7 and R9 are each substituted or unsubstituted lower alkyl group, Rg and RIO are lower alkyl group, hydroxyalkyl group, sulfoalkyl group, carboxyalkyl group; Xl is an anion; zl and z2 are nonmetallic atomic groups necessary to complete a substituted or unsubstituted benzene ring; (However, when forming an inner salt, the swelling is l.)] The emulsion forming the X-ray sensitive material of the present invention has the general formula CII
) When using the compound (III), it is preferable that at least 95% of the weight or number of silver halide grains contained in the silver halide emulsion have a grain size within ±4C1 of the average grain size. .
次に、式CII (I[]則〕の化合物について更に説
明する。Next, the compound of formula CII (I[] rule) will be further explained.
一般式CIIにおいて、R1#”2 pR5の置換もし
くは非置換のアルキル基としては、具体的には例えばメ
チル、エチル、n−プロピルまたはブチル等の低級アル
キル基を挙げることができる。al +RZ tB5
の置換アルキル基としては、ビニルメチル等を挙げる
ことができ、また、ヒドロキシアルキル基として2−ヒ
ドロキシエチル、4−ヒドロキシブチル等、アセト牟ジ
アルキル基として2−アセ14ジブチル、3−アセ14
ジブチル等、カルボキンアルキル基として2−カルボキ
シエチル、3−カルボキシプロピル、2−(2−カルボ
キシエト中シ)エチル等、スルホアルキル基として2−
スルホエチル、3−スルホプロピル、3−スルホブチル
、4−スルホブチル、2−ヒドロキシ−3−スルホプロ
ピル等を挙げることができる。R1゜R2,Jのアルケ
ニル基としてはアリル、ブチニル、オクテニルまたはオ
レイル等が挙げられる。更にR1tR2tR5のアリー
ル基としては、例えば、フェニル、カルボキシフェニル
等が挙げられる。但り創記の通シ、R1sR2eR5の
内少なくとも1つはスルホアルキル基またはカルボキン
アルキル基である。In general formula CII, the substituted or unsubstituted alkyl group of R1#"2 pR5 can specifically include, for example, a lower alkyl group such as methyl, ethyl, n-propyl or butyl. al +RZ tB5
Examples of substituted alkyl groups include vinylmethyl, hydroxyalkyl groups include 2-hydroxyethyl, 4-hydroxybutyl, etc., and acetodialkyl groups include 2-ace14 dibutyl, 3-ace14
Dibutyl etc., carboxyl alkyl group such as 2-carboxyethyl, 3-carboxypropyl, 2-(2-carboxyethyl)ethyl etc., sulfoalkyl group 2-
Examples include sulfoethyl, 3-sulfopropyl, 3-sulfobutyl, 4-sulfobutyl, 2-hydroxy-3-sulfopropyl, and the like. Examples of the alkenyl group for R1°R2,J include allyl, butynyl, octenyl, and oleyl. Furthermore, examples of the aryl group of R1tR2tR5 include phenyl, carboxyphenyl, and the like. However, as a general rule, at least one of R1sR2eR5 is a sulfoalkyl group or a carboxynealkyl group.
また式〔I〕においてxl で示されするアニオンとし
ては、例えば塩素イオン、臭素イオン、沃素イオン、チ
オシア/酸イオン、硫酸イオン、過塩素酸イオン、p−
トルエンスルホン酸イオン、エチル硫酸イオン等を挙げ
ることができる。Examples of the anion represented by xl in formula [I] include chloride ion, bromide ion, iodide ion, thiocyanate/acid ion, sulfate ion, perchlorate ion, p-
Examples include toluenesulfonate ion, ethylsulfate ion, and the like.
次にこの一般式CIIで表わされる化合物の代表的な具
体例を挙げるが、本発明はこれによって限定されるもの
ではない。Next, typical examples of the compound represented by the general formula CII will be given, but the present invention is not limited thereto.
(化 合 物 例)
3”ゝ 。、H5(2)
。t HS占H□CHt COO
HCH! CH* OCH意CHISO!−(6)
C* H5(
7) CJs
(C’Hx) OCOCHs
(1G) Cx Hs(1
1) CgHs′12)
。t)la(13)
CwHs(14)
。3H3(16)
。□、0H8゜。H8゜□、
。□Cx Hs
C*Hs (CH霊)#SO!
−しi3
(21) 。gHsl
CHs (CHJ#5Ch−Cm
Hs
(23) 。l HS■
(2“) 。aHqMaHq
(CHs)*5Os−C冨Hs
(CHJsSOsH(CHt)sS()+−C*Hs
(CHs)ySOx−CtHs
C冨Hも
C,H%
(CHm)sS Os−CtHs
CtHs
(CHs)sSCh−CtHs
Ct Hs
■
CtHs (CHz)sSO
ff−CtHs
(3日)
CtHs
CtHs
■
CtHs
■
式[11]において、R6は水素原子、低級アルキル基
、アリール基を表わすが、低級アルキル基としては、メ
チル、エチル、プロピル、ブチル等の基が挙げられる、
アリール基の例としては1例(A21
のR+、R3として例示したものを挙げることができる
。Xlのアニオンも、式[I]のXτとして例示したも
のを挙げることができる。(Compound example) 3”ゝ., H5(2)
. t HS fortune H□CHt COO
HCH! CH*OCH CHISO! -(6)
C*H5(
7) CJs
(C'Hx) OCOCHs (1G) Cx Hs(1
1) CgHs'12)
. t)la(13)
CwHs (14)
. 3H3 (16)
. □, 0H8°. H8゜□,
. □Cx Hs C*Hs (CH spirit) #SO!
-shii3 (21). gHsl CHs (CHJ#5Ch-Cm
Hs (23). l HS■ (2") .aHqMaHq
(CHs)*5Os-CtHs (CHJsSOsH(CHt)sS()+-C*Hs (CHs)ySOx-CtHs C-toH is also C, H% (CHm)sS Os-CtHs CtHs (CHs)sSCh-CtHs Ct Hs ■ CtHs (CHz)sSO
ff-CtHs (3 days) CtHs CtHs ■ CtHs ■ In formula [11], R6 represents a hydrogen atom, a lower alkyl group, or an aryl group, and as a lower alkyl group, groups such as methyl, ethyl, propyl, butyl, etc. can be mentioned,
Examples of the aryl group include those exemplified as R+ and R3 in A21. Examples of the anion of Xl include those exemplified as Xτ in formula [I].
次に式[II]で表わされる化合物の代表的な具体例を
挙げるが、勿論この場合もこの例示により (AA1
本発明が限定されるものではない。Next, typical specific examples of the compound represented by the formula [II] will be given, but of course, in this case as well, based on this example (AA1
The present invention is not limited.
[有]
Aへ1
CH重CHzSOsHCHzCHtSOs(CHt)s
SChNa (CHz)ssOs−C
tHs (CHz)ss
OsCHICHtCHxSOsHCHtCH*CHtS
Os次に式圓においては、R7、R9の低級アルキル基
としては、メチル、エチル、プロピル、ブチル等の基を
例示できる。置換アルキル基としては、式〔I〕におい
てR1−R5につき例示した基を挙げることができる。[Yes] To A 1 CH heavy CHzSOsHCHzCHtSOs(CHt)s
SChNa (CHz)ssOs-C
tHs (CHz)ss
OsCHICHtCHxSOsHCHtCH*CHtS
Os Next, in the formula circle, examples of lower alkyl groups for R7 and R9 include methyl, ethyl, propyl, butyl and the like. Examples of substituted alkyl groups include the groups exemplified for R1 to R5 in formula [I].
”8 e RIOの低級アルキル基はRτ、Rつと同じ
ものを例示できる。またR85RIGのヒドロキシアル
午ル基、スルホアルキル基、カルボキシアルキル基とし
ては式CIIにおいてR1−R5につき例示した基を挙
げることができる。Examples of the lower alkyl group in 8e RIO include the same groups as Rτ and R. Examples of the hydroxyalkyl group, sulfoalkyl group, and carboxyalkyl group in R85RIG include the groups exemplified for R1 to R5 in formula CII. I can do it.
X3−のアニオンも式のXl−として例示したものを挙
げることができる。Examples of the anion of X3- include those exemplified as Xl- in the formula.
かかる式(資)で表わされる化合物の代表的な具体例を
次に挙げる。勿論この場合もこの例示により本発明は限
定されるものではない。Typical specific examples of compounds represented by the formula (2) are listed below. Of course, the present invention is not limited to this example either.
(化合物例)
C2H5(CH2)IISO5−
上記式CI) [:II](8)で示される化合物の添
加総量はハロゲン化銀1モルに対し、101NI〜90
0wpo範囲で用いることができる。特1c、60〜6
0011Qが好ましい。(Compound example) C2H5(CH2)IISO5- The total amount of the compound represented by the above formula CI) [:II] (8) is 101 NI to 90 NI per mol of silver halide.
It can be used in the 0wpo range. Special 1c, 60-6
0011Q is preferred.
成長粒子に施す化学増感法としては、例えば、チオ硝酸
ナトリウム、チオ尿素化合物等を用いる硫黄増感法、塩
化金酸塩、三塩化金等を用いる金増感法、二数化チオ尿
素、塩化第一錫、銀熟成等を用いる還元増感法、その他
パラジウム増感法、セレン増感法等があシ、これらを単
独でもちいたり、これらを二種以上併用したりすること
ができるO
この場合、特に金増感と硫黄増感を併用することが好ま
しい。Chemical sensitization methods applied to grown particles include, for example, sulfur sensitization methods using sodium thionitrate, thiourea compounds, etc., gold sensitization methods using chloroaurates, gold trichloride, etc., divalent thiourea, There are reduction sensitization methods using stannous chloride, silver ripening, etc., palladium sensitization methods, selenium sensitization methods, etc., and these methods can be used alone or in combination of two or more. In this case, it is particularly preferable to use gold sensitization and sulfur sensitization together.
本発明の実施においては、I・ログン化銀乳剤中のハロ
ゲン化銀粒子としては、0.3〜3μmの平均粒径をも
つものを使用することができる。In the practice of the present invention, silver halide grains in the I-logonide emulsion may have an average grain size of 0.3 to 3 .mu.m.
このようなハロゲン化銀粒子の内部には、少なくとも2
0モルチ以上の高濃度のヨウ化銀が局在化した局在化部
分が存在することが好ましい。Inside such silver halide grains, there are at least two
It is preferable that a localized portion in which silver iodide is localized at a high concentration of 0 molti or more is present.
この場合、粒子内部としては、粒子の外表面からできる
だけ内側にあることが好ましく、特に外表面から0.O
IAm以上離れた部分に局在部分が存在することが好ま
しい。In this case, the inside of the particle is preferably located as far inward as possible from the outer surface of the particle, particularly within 0.000 m from the outer surface. O
It is preferable that the localized portion exists at a distance of IAm or more.
また、局在化部分は、粒子内部にて、層状に存在しても
よく、またいわゆるコアシェル構造をとって、そのコア
全体が局在化部分となっていてもよい。この場合、外表
面から0.01μm以上の厚さのシェル部分を除く粒子
コア部の一部ないし全部が、20モルチ以上のヨウ化銀
濃度の局在化部分であることが好ましい。Further, the localized portion may exist in a layered manner inside the particle, or may have a so-called core-shell structure, with the entire core serving as the localized portion. In this case, it is preferable that part or all of the grain core part excluding the shell part having a thickness of 0.01 μm or more from the outer surface is a localized part with a silver iodide concentration of 20 molti or more.
なお、局在化部分のヨウ化銀は、その濃度が30〜40
モル係の範囲であることが好ましい。In addition, the concentration of silver iodide in the localized portion is 30 to 40
The molar ratio is preferably within the range.
本発明の実施において、そのノ)ロゲン化銀乳剤中に用
いるハロゲン化銀粒子は、例えばT、H,James著
@The Th@ory of the Photog
raphic Process’第4版、Macm11
1an社刊(1977年)88〜104頁等の文献に記
載されている中性法、酸性法、アンモニア法、順混合、
逆混合、ダブルジェット法、コンドロールド−ダブルジ
ェット法、コンヴアージ:!ノ法、コア/シェル法など
の方法を適用して製造することができる。ハロゲン化銀
組成としては、塩化銀、臭化銀、塩臭化銀、沃臭化銀、
塩沃臭化銀などのいずれも用いることができるが、最も
好ましい乳剤は、約10モルチ以下の沃化銀を含む沃臭
化銀乳剤である。In the practice of the present invention, the silver halide grains used in the silver halide emulsion are described, for example, by T. H. James @The Th@ory of the Photog
rapic Process' 4th edition, Macm11
Neutral method, acidic method, ammonia method, forward mixing, etc. described in literature such as 1ansha (1977) pp. 88-104,
Back mixing, double jet method, chondral double jet method, convourage:! It can be manufactured by applying a method such as a core/shell method or a core/shell method. Silver halide compositions include silver chloride, silver bromide, silver chlorobromide, silver iodobromide,
The most preferred emulsions are silver iodobromide emulsions containing less than about 10 moles of silver iodide, although any silver chloroiodobromide emulsion can be used.
ハロゲン化銀粒子の粒子サイズは、特に制限は無いが、
0.1〜3μのものが好ましく、更に好ましくは0.3
〜2μである。またこれらのノ・ロゲン化銀粒子又はハ
ロゲン化銀乳剤中には、閃光露光特性の改良の為に、イ
リジウム塩および/またはR4゜
銀を含まないノ・ロゲン化銀によって被覆される。There are no particular restrictions on the grain size of silver halide grains, but
Preferably 0.1 to 3μ, more preferably 0.3μ
~2μ. Further, these silver halide grains or silver halide emulsions are coated with iridium salt and/or silver halide containing no R4° silver in order to improve flash exposure characteristics.
すなわち、好ましい態様においては、外表面から0.0
IJjrn以上、特に0.01〜1.5 Amの厚さの
シェル部分がヨウ化銀を含まないノ・ロゲン化銀(通常
、臭化銀)で形成される。That is, in a preferred embodiment, the distance from the outer surface is 0.0
The shell portion with a thickness of IJjrn or more, especially from 0.01 to 1.5 Am, is made of silver iodide-free silver halide (usually silver bromide).
本発明において、粒子内部(好ましくは粒子外壁からo
、oiμm以上離以上−る粒子の内側)に少なくとも2
0モル係以上の高濃度ヨウ化銀の局在化部分を形成する
方法としては、種晶を使うものが好ましいが、種晶を使
わないものであってもよい。In the present invention, from the inside of the particle (preferably from the outer wall of the particle)
, inside the particles separated by at least oi μm).
As a method for forming localized portions of high concentration silver iodide with a molar ratio of 0 or more, it is preferable to use seed crystals, but methods that do not use seed crystals may also be used.
種晶を使わない場合は、保護ゼラチンを含む反応液相(
以後、母液という)中に、熟成開始前は成長核となるよ
うなハロゲン化銀がないので、まず銀イオンおよび少な
くとも20モルチ以上の高濃度ヨウ素イオンを含むハラ
イドイオンを供給して成長核を形成させる。そして、さ
らに添加供給を続けて、成長核から粒子を成長させる。If seed crystals are not used, the reaction liquid phase containing the protected gelatin (
Since there is no silver halide that can serve as growth nuclei in the mother liquor (hereinafter referred to as mother liquor) before the start of ripening, first, silver ions and halide ions containing high concentration iodine ions of at least 20 molti are supplied to form growth nuclei. let Then, additional supply is continued to grow particles from the growth nuclei.
最後に、ヨウ化銀を含まないハロゲン化銀で0.01μ
m以上の厚さをもつシェル層を形成せしめる。Finally, add 0.01μ of silver halide that does not contain silver iodide.
A shell layer having a thickness of m or more is formed.
種晶を使う場合には、種晶のみに少なくとも20モルチ
以上のヨウ化銀を形成し、こののちシェル層で被覆して
もよい。あるいは、種晶のヨウ化銀量をOとするか10
モルチ以下の範囲内とし、種晶を成長させる工程で粒子
内部に少なくとも20モルチのヨウ化銀を形成させて、
こののちシェル層で被覆してもよい。When using seed crystals, at least 20 mol of silver iodide may be formed only on the seed crystals, and then covered with a shell layer. Alternatively, the amount of silver iodide in the seed crystal is O or 10
within the range of less than molt, and at least 20 molt of silver iodide is formed inside the grains in the step of growing seed crystals,
This may be followed by coating with a shell layer.
この場合、本発明においては、粒子全体では全ハロゲン
化銀に対してヨウ化銀の割合が0.5〜10こ13と
モルチの範囲内−1前者の方法では種晶の粒径が後者に
比べて失色くなり、粒子サイズの分布が広くなる。後者
のように多重構造をもつものの方が本発明においては好
ましい。本発明の好ましい一実施態様は、構造又は形態
が規則正しいハロゲン化銀粒子を用いることである。即
ち、ハロゲン化銀粒子の重量又は粒子数で少なくとも8
0チが規則正しい形であるハロゲン化銀乳剤を用いる。In this case, in the present invention, the ratio of silver iodide to the total silver halide in the entire grain is within the range of 0.5 to 10 to 13, which is within the range of 1-1. In comparison, the color is lost and the particle size distribution is wider. The latter having a multiple structure is preferable in the present invention. A preferred embodiment of the present invention is to use silver halide grains with regular structure or morphology. That is, the weight or number of silver halide grains is at least 8.
A silver halide emulsion in which 0's have a regular shape is used.
本発明に用いられる、構造又は形態が規則正しいハロゲ
ン化銀粒子とは、
双晶面等の異方的成長を含まず、全て等方的に成長する
粒子を意味し、例えば立方体、14面体、正8面体、球
型等の形状を有する。かかる規則正しいハロゲン化銀粒
子の製法は公知であり、例えばJ、Phot、Sai、
、5,332 (1961)、B@r、Bunaen−
ges、Phys、Cham、67,949 (196
3)、工nt・rn。The silver halide grains with a regular structure or morphology used in the present invention mean grains that grow isotropically without including anisotropic growth such as twin planes, such as cubic, tetradecahedral, and regular grains. It has an octahedral, spherical, etc. shape. Methods for producing such regular silver halide grains are known, for example, J. Phot, Sai;
, 5, 332 (1961), B@r, Bunaen-
ges, Phys, Cham, 67,949 (196
3), engineering nt・rn.
Congress Phot、Sci、Tokyo (
1967)等に記載されている。Congress Photo, Sci, Tokyo (
1967) and others.
かかる規則正しいハロゲン化銀粒子は、同時混合法を用
いてノ・ロゲン化銀粒子を成長させる際の反応条件を調
節することにより得られる。かかる同時混合法において
は、ノ・ロゲン化銀粒子は、保護コロイドの水溶液中へ
激しく撹拌しつつ、硝散銀溶液とハロゲン化物溶液とを
ほぼ等量づつ添加することKよシ作られる。Such regular silver halide grains can be obtained by adjusting the reaction conditions when growing silver halide grains using a simultaneous mixing method. In such a simultaneous mixing method, silver halide grains are prepared by adding approximately equal amounts of a silver nitrate solution and a halide solution to an aqueous solution of a protective colloid while stirring vigorously.
そして、銀イオンおよびノーライドイオンの供給は、結
晶粒子の成長に伴って、既存結晶粒子を溶失させず、ま
た逆に新規粒子の発生、成長を許さない、既存粒子のみ
の成長に必要十分なノ・ロゲン化銀を供給する限界成長
速度、あるいはその許容範囲、において、成長速度を連
続的にあるいは段階的に逓増させることが好ましい。こ
の逓増方法としては持分111848−36890号、
同52−16364号、特開昭55−142329号公
報に記載されている。The supply of silver ions and noride ions is necessary and sufficient for the growth of only existing grains, without dissolving the existing crystal grains as the crystal grains grow, and conversely not allowing the generation and growth of new grains. It is preferable to increase the growth rate continuously or stepwise within the critical growth rate for supplying silver halogenide, or within its permissible range. As this increasing method, equity No. 111848-36890,
It is described in No. 52-16364 and Japanese Unexamined Patent Publication No. Sho 55-142329.
この限界成長速度は、温度1)HSPAgs撹拌の程度
、ノーロゲン化銀粒子の組成、溶解度、粒径、粒子間距
離、晶癖、あるいは保護コロイドの種類と濃度等によっ
て変化するものではあるが、液相中に懸濁する乳剤粒子
の顕微鏡観察、濁度測定等の方法により実験的に容易に
求めることができる。This critical growth rate varies depending on temperature, 1) degree of HSPAgs agitation, composition of silver noloride grains, solubility, grain size, interparticle distance, crystal habit, or type and concentration of protective colloid, etc. It can be easily determined experimentally by methods such as microscopic observation of emulsion particles suspended in the phase and turbidity measurement.
そして、この畝界添加速度あるいはその許容範囲内にお
いて、添加速度を逓増させることによシ、単分散乳剤、
つまシ変動係数が20%以下のものが得られる。Then, by increasing the addition rate at this furrow addition rate or within its allowable range, monodispersed emulsions,
A piece with a coefficient of variation of 20% or less can be obtained.
上記単分散乳剤を得るためには、特に種晶を用い、この
種晶を成長核として、銀イオンおよびハライドイオンを
供給することによシ、粒子を成長させることが好ましい
。In order to obtain the above-mentioned monodisperse emulsion, it is particularly preferable to use seed crystals and grow grains by supplying silver ions and halide ions using the seed crystals as growth nuclei.
この種晶の粒子サイズの分布が広いほど、粒子成長後の
粒子サイズ分布も広くなる。従って、単分散乳剤を得る
ためには、種晶の段階で粒子サイズ分布の狭いものを用
いるのが好ましい。The wider the particle size distribution of this seed crystal, the wider the particle size distribution after particle growth. Therefore, in order to obtain a monodisperse emulsion, it is preferable to use seed crystals with a narrow particle size distribution at the seed crystal stage.
本発明の実施に際しては、上記の如き化学増感前の粒子
成長中に、保護コロイドを含む母液のpAgが少なくと
も10.5以上である態様を好ましく採用できる。In carrying out the present invention, it is preferable to adopt an embodiment in which the mother liquor containing the protective colloid has a pAg of at least 10.5 during particle growth before chemical sensitization as described above.
特に好ましくは11.5以上の非常にブロムイオンが過
剰な雰囲気を一度でも通過させる。Particularly preferably, an atmosphere with a very high bromine ion excess of 11.5 or more is passed through at least once.
このようにして(111)面を増加させて粒子を丸める
ことにより、本発明の効果を一層高めることができる。By increasing the number of (111) planes and rounding the particles in this way, the effects of the present invention can be further enhanced.
このような粒子の(ill)面は、その全表面積に対す
る割合が5チ以上であることが好ましい。The ratio of the (ill) plane of such particles to the total surface area is preferably 5 or more.
この場合、(Ill)面の増加率(上記の10.5以上
のPAg雰囲気を通過させる前のものに対する増加率)
は10%以上、よシ好ましくは10〜20チとなること
が好ましい。In this case, the increase rate of the (Ill) plane (the increase rate with respect to that before passing through the PAg atmosphere of 10.5 or more above)
is preferably 10% or more, more preferably 10 to 20%.
ハロゲン化銀粒子外表面を(lll)面もしくは(10
0)面のどちらかが覆っているか、あるいはその比塞を
どのように測定するかについては、平田明による報告、
′ブレチン オブ ザ ソサイアテイ オブ サイエ
ンティフィック フォトグラフィ オブ ジャパン″A
13 、5〜15ページ(19、63)に記載されて
いる。The outer surface of the silver halide grain is the (llll) plane or the (10
0) Regarding whether one of the surfaces is covered or how to measure its density, please refer to the report by Akira Hirata.
``Bulletin of the Society of Scientific Photography of Japan''A
13, pp. 5-15 (19, 63).
本発明において、化学増感前の粒子成長中に、保護コロ
イドを含む母液のpAgが少なくともlO05以上であ
る雰囲気を一度通過させることにより、平田の測定方法
によって、(Ill)面が5%以上増加しているか否か
は容易に確認することができる。In the present invention, by once passing through an atmosphere in which the pAg of the mother liquor containing protective colloid is at least 1O05 during grain growth before chemical sensitization, the (Ill) plane increases by 5% or more according to Hirata's measurement method. You can easily check whether this is the case.
この場合、上記PAgとする時期は、化学増感前である
が、ハロゲン化銀粒子の成長のために銀イオンを添加す
る時期から脱塩工程前が好ましく、特に銀イオンの添加
終了後であって、化学増感前に通常行われているいわゆ
る脱塩工程前であることが望ましい。これは、粒径分布
の狭い単分散乳剤が得やすいからである。In this case, the above-mentioned PAg is applied before chemical sensitization, but preferably from the time when silver ions are added for the growth of silver halide grains to before the desalting process, especially after the addition of silver ions is completed. Therefore, it is preferable to carry out the so-called desalting step which is usually carried out before chemical sensitization. This is because it is easy to obtain a monodispersed emulsion with a narrow particle size distribution.
なお、pAgが1000以上である雰囲気での熟成は、
2分以上行うことが好ましい。In addition, aging in an atmosphere where pAg is 1000 or more,
It is preferable to do this for 2 minutes or more.
このようなPAg制御により、(111)面が5−以上
増加し、形状が丸みを帯qることになる。この結果、粒
子の(tii)面が粒子全表面積の5チ以上となる好ま
しいものを得ることができる。By such PAg control, the number of (111) planes increases by 5 or more, and the shape becomes rounded q. As a result, it is possible to obtain a preferable particle in which the (tii) plane is 5 or more of the total surface area of the particle.
このようにして調製されたハロゲン化銀乳剤には、化学
増感の終了後に、安定剤を加えることができる。例えば
、4−ヒドロキシ−6−メチル−1,3,3畠、7−テ
ト乏ザイデン、5−メルカプト−1−フェニルテトラゾ
ール、2−メルカプトベンゾチアゾールなどをはじめ、
当業界で公知の安定剤はいずれも使用できる。A stabilizer can be added to the silver halide emulsion thus prepared after completion of chemical sensitization. For example, 4-hydroxy-6-methyl-1,3,3-hatake, 7-tetopozyden, 5-mercapto-1-phenyltetrazole, 2-mercaptobenzothiazole, etc.
Any stabilizer known in the art can be used.
本発明のハロゲン化銀写真乳剤は、ベヒクルの保護コロ
イドとしてゼラチン、ゼラチン誘導体、合成親水性ポリ
マー等を用いることができ、さらに種々の写真用添加剤
を含ませることができる。The silver halide photographic emulsion of the present invention can use gelatin, a gelatin derivative, a synthetic hydrophilic polymer, etc. as a protective colloid for the vehicle, and can further contain various photographic additives.
硬膜剤としては、アルテ“とド化合物、S−トリアジン
化合物、ケトン化合物、ムコクロル酸のようなハロゲン
置換酸、エチレンイミン化合物、ビニルスルホフオン化
合物等を用いることができる。As the hardening agent, an arte compound, an S-triazine compound, a ketone compound, a halogen-substituted acid such as mucochloric acid, an ethyleneimine compound, a vinyl sulfofone compound, etc. can be used.
延展剤としては、サポニン、ポリエチレングリゴールの
ラウリルまたはオレイルモノエーテル等が用いられる。As the spreading agent, saponin, lauryl or oleyl monoether of polyethylene glycol, etc. are used.
現像促進剤としては特に制限はないが、チオエーテル化
合物、ペイライミダゾール化合物(例えば特開昭49−
24427号公報記載のもの)、4級アンモニウム塩、
ポリエチレングリゴール等の化合物を用いることができ
る。There are no particular restrictions on the development accelerator, but thioether compounds, pei-raimidazole compounds (e.g.,
24427), quaternary ammonium salt,
Compounds such as polyethylene glycol can be used.
物性改良剤としては、アルキルアクリレート、アル午ル
メタアクリレート、アクリル酸等のホモまたはコポリi
−からなるポリマークッテクス等を含有せしめることが
できる。As a physical property improver, homo or copolymer such as alkyl acrylate, alkyl methacrylate, acrylic acid, etc.
- It is possible to contain a polymer coating consisting of - or the like.
そして本発明のハロゲン化銀写真乳剤には、フェノール
アルデヒド縮金物にグリシドールおよびエチレンオキサ
イドを付加共重合させて得られる化合物(例えば特開昭
51−56220号公報記載のもの)、ラノリン系エチ
レンオキサイド付加体とアルカリ金属塩および/または
アルカリ土類金属(例えば特開昭53−145022号
公報記載のもの)、水溶性無機塩化物およびマット剤(
特願昭54−69242号)、フェノールアルデヒド縮
金物にグリシドールおよびエチレンオキサイドを付加縮
合させた付加縮合物と含フツ素コハク酸化合物(特願昭
52−104940号)等の帯電防止剤を添加すること
ができる。The silver halide photographic emulsion of the present invention includes a compound obtained by addition copolymerizing glycidol and ethylene oxide to a phenol aldehyde condensate (for example, the one described in JP-A-51-56220), a lanolin-based ethylene oxide addition body, alkali metal salts and/or alkaline earth metals (for example, those described in JP-A-53-145022), water-soluble inorganic chlorides, and matting agents (
(Japanese Patent Application No. 54-69242), an addition condensate of glycidol and ethylene oxide to a phenolaldehyde condensate, and an antistatic agent such as a fluorine-containing succinic acid compound (Japanese Patent Application No. 104940/1982) are added. be able to.
さらにはpH調整剤、増粘剤、粒状性向上剤、膜面改良
マット剤などを含有させることができる。Furthermore, a pH adjuster, a thickener, a graininess improver, a film surface improving matting agent, etc. can be contained.
本発明の感光材料を得る場合の支持体としては、ポリエ
チレンテレフタレート、ポリカーボネート、ポリスチレ
ン、ポリプロピレン、セルロースアセテート等からなる
フィルムを用いることができる。As a support for obtaining the light-sensitive material of the present invention, a film made of polyethylene terephthalate, polycarbonate, polystyrene, polypropylene, cellulose acetate, etc. can be used.
また支持体としては、特開昭52−104913、特開
昭59−19941、特開昭59−19940、特開昭
59−18949に記載されていた下引き処理を行なっ
たものが好ましい。The support is preferably one that has been subjected to the subbing treatment described in JP-A-52-104913, JP-A-59-19941, JP-A-59-19940, and JP-A-59-18949.
以下、本発明の具体的実施例について述べる。 Hereinafter, specific examples of the present invention will be described.
但し、以下の実施例は本発明の例証であって、本発明が
これにより限定されるものではない。However, the following examples are illustrative of the present invention, and the present invention is not limited thereto.
実施例1
以下述べるように6種類の乳剤I−1〜I−6を調製し
fc、。Example 1 Six types of emulsions I-1 to I-6 were prepared as described below.
まず、層温合法により、沃化銀2.0 motチを含む
沃臭化銀多分散乳剤(I−1)を得た。First, a polydispersed silver iodobromide emulsion (I-1) containing 2.0 mots of silver iodide was obtained by a layer heating method.
乳剤I−2は、次の方法で調製した。Emulsion I-2 was prepared by the following method.
ゼラチン水溶液中に、沃化カリウム2.0モルチを含む
臭化カリウム溶液とアンモニア性硝酸銀溶液とをダブル
ジェット法で流速を徐々に速めながら添加して、1.0
5μmの沃臭化銀立方晶単分散性乳剤を得た。更にアン
モニア性硝酸銀溶液と臭化カリウム溶液とをダブルジェ
ット法で添加して純臭化銀のシェルをかぶせた。この間
PAgは10.OK保ち、pHは9.0から8.0に徐
々に低下させた。A potassium bromide solution containing 2.0 mol of potassium iodide and an ammoniacal silver nitrate solution were added to an aqueous gelatin solution using a double jet method while gradually increasing the flow rate to obtain a solution of 1.0 mol of potassium iodide.
A 5 μm silver iodobromide cubic monodisperse emulsion was obtained. Further, an ammoniacal silver nitrate solution and a potassium bromide solution were added by a double jet method, and a shell of pure silver bromide was covered. During this period, PAg was 10. The pH was gradually lowered from 9.0 to 8.0 while maintaining OK.
これKより、平均粒径1.25μmの立方晶単分散乳剤
l−2−2を得た。また、この乳剤l−2−2と同様な
方法によプ、平均粒径1.65μmの立方晶単分散乳剤
l−2−1、及び平均粒径0.65μmの立方晶単分散
乳剤l−3−1を得た。この乳剤l−2−1と、上記乳
剤l−2−,2とを、下記表に示す如(10:90の混
合比で混合して、試料とじての乳剤I−2を得た。From this K, a cubic monodisperse emulsion 1-2-2 having an average grain size of 1.25 μm was obtained. Further, by the same method as this emulsion 1-2-2, a cubic monodisperse emulsion 1-2-1 with an average grain size of 1.65 μm and a cubic monodisperse emulsion 1- with an average grain size of 0.65 μm were prepared. I got 3-1. This emulsion 1-2-1 and the above emulsion 1-2-, 2 were mixed at a mixing ratio of 10:90 as shown in the table below to obtain emulsion I-2 as a sample.
また上記乳剤l−2−2とl−3−1とを下記表に示す
如(75:25の混合比で混合して、試料としての乳剤
I−3を得九。Further, the emulsions I-2-2 and I-3-1 were mixed at a mixing ratio of 75:25 as shown in the table below to obtain emulsion I-3 as a sample.
次に、下記の如く乳剤I−4〜I−6を得た。Next, emulsions I-4 to I-6 were obtained as described below.
60℃、pAg=8、pH=2−0にコントロールしつ
つ、ダブルジェット法で平均粒径0.3μmの、ヨウ化
銀2.0モル係を含むヨク臭化銀乳剤の単分散立方晶乳
剤を得た。この乳剤の電子顕微鏡写真から、双晶粒子の
発生率は、個数で1%以下でおった。A monodisperse cubic emulsion of silver bromide emulsion containing 2.0 mol of silver iodide and having an average grain size of 0.3 μm was prepared by the double jet method while controlling the temperature at 60°C, pAg=8, and pH=2-0. I got it. An electron micrograph of this emulsion showed that the incidence of twin grains was less than 1% in number.
この乳剤の一部を種晶として用い、以下のように成長さ
せた。A portion of this emulsion was used as a seed crystal and grown as follows.
すなわち、40℃に保たれた保護ゼラチンおよび必要に
応じてアンモニアを含む溶液8.56に、この種晶を溶
解させ、さらに氷酢酸によシpHを調整したO
この液を母液として、3.2規定のアンモニア性銀イオ
/水溶液およびハライド水溶液を、ダブルジェット法で
、第Zri!JK示されるような流量パターンで添加し
、撹拌、混合を行った。That is, the seed crystals were dissolved in a solution 8.56 containing protected gelatin and optionally ammonia kept at 40°C, and the pH was adjusted using glacial acetic acid.3. 2N ammoniacal silver ion/aqueous solution and halide aqueous solution by double jet method, No. Zri! The mixture was added according to the flow rate pattern shown in JK, and stirring and mixing were performed.
この場合、この母液のアンモニア濃度0.6N。In this case, the ammonia concentration of this mother liquor is 0.6N.
pH9,7、pAg 7.6とすることにより、内部に
、30 mot% Q 1り化銀を局在化させた。By adjusting the pH to 9.7 and pAg to 7.6, 30 mot% Q silver monoxide was localized inside.
次にpAgを9.0の一定に保ち、アンモニア性銀イオ
ンの添加量に比例してpHを9から8へ変化させて、純
臭化銀のシェルを形成した。更に粒子成長の終了時の3
分間pAgf、11.5にして熟成を行い、粒子を丸め
た。Next, the pAg was kept constant at 9.0, and the pH was changed from 9 to 8 in proportion to the amount of ammoniacal silver ions added to form a shell of pure silver bromide. Furthermore, 3 at the end of grain growth
Aging was performed at a pAgf of 11.5 minutes and the particles were rounded.
このようにして、第2表に示される7種類の単分散乳剤
l−4−1〜l−6−3を作製した。In this way, seven types of monodispersed emulsions 1-4-1 to 1-6-3 shown in Table 2 were prepared.
乳剤I−4〜I−6の3つは、前記乳剤I−1と同様の
方法で調tした、各々平均粒径の異なる3種の内部高ヨ
ード型単分散乳剤を混合して得たものである。つマシ、
乳剤I−4及びI−5は、平均粒径0.90μの乳剤(
I−4−1) 、 0.70μの乳剤(I−4−2)、
0.35μの乳剤(I−4−3)をそれぞれ9ニア3:
18及び13:67:20の混合比で混合して得た。ま
た乳剤I−6は、平均粒径0.95μの乳剤(I−6−
1)、 0.80μの乳剤(I−6−2) 、 0.5
0μの乳剤(I−6−3)を22:48:30の混合比
で混合して得た。各試料の組成をまとめて下記表−2に
示すO
表−2
上記のようにして得られた乳剤l−4−1−l−4−3
゜l−6−1−l−6−3(つまり乳剤I−4〜I−6
を構成する各乳剤)には、下記化合物■、■、■の増感
色素を加え、その後チオシアン酸アンモニウムド塩化金
酸とハイポを加えて、金−硫黄増感を行った。Three emulsions I-4 to I-6 were obtained by mixing three types of internally high iodine type monodisperse emulsions, each having a different average grain size, prepared in the same manner as the emulsion I-1. It is. Tsumashi,
Emulsions I-4 and I-5 are emulsions with an average grain size of 0.90μ (
I-4-1), 0.70μ emulsion (I-4-2),
0.35μ emulsion (I-4-3) respectively 9nia 3:
It was obtained by mixing 18 and 13:67:20. Emulsion I-6 is an emulsion with an average grain size of 0.95μ (I-6-
1), 0.80μ emulsion (I-6-2), 0.5
A 0μ emulsion (I-6-3) was obtained by mixing at a mixing ratio of 22:48:30. The composition of each sample is summarized in Table 2 below.Table 2 Emulsion l-4-1-l-4-3 obtained as above
゜l-6-1-l-6-3 (that is, emulsions I-4 to I-6
To each of the emulsions constituting the emulsions), sensitizing dyes of the following compounds (1), (2), and (2) were added, and then ammonium thiocyanate dichloroauric acid and Hypo were added to perform gold-sulfur sensitization.
その他の乳剤については、増感色素は添加せずに、同じ
金−硫黄増感を行った。よって、試料I−4〜I−6は
オルソ増感したオルソタイプであるが、他はレギュラー
タイプである。増感色素として加えた化合物■は前記式
〔工〕で表わされるものの1種であり、化合物■は式〔
■〕、化合物■は式(資)で表わされるものの各々1種
である。各化合物の式%式%
(本発明の化合物)
化合物 ■
C2H。The other emulsions were subjected to the same gold-sulfur sensitization without adding any sensitizing dye. Therefore, samples I-4 to I-6 are ortho-sensitized orthotypes, while the others are regular types. The compound ■ added as a sensitizing dye is one of the compounds represented by the above formula [E], and the compound ■ is represented by the formula [E]
(2)] and Compound (2) are each one of the compounds represented by the formula (I). Formula % of each compound Formula % (Compound of the present invention) Compound ■ C2H.
■
化合物 ■
化合物 ■
そして、通常の安定剤、硬膜剤、塗布助剤を加え丸後、
グリシジルメタクリレート5 Q vt%、メチルアク
リレートi o vttsl ブチルメタクリレ−)
40 vt%の三種のモノマーからなる共重合体を、そ
の濃度が10 vt9Jになるように希釈して得た共重
合体水性分散液を下引無液として塗設したポリエチレン
テレフタレートフィルムベース上ニ、コの乳剤を両面に
均一塗布、乾燥し、センシトメトリー試料を得た。■ Compound ■ Compound ■ Then, add the usual stabilizers, hardeners, and coating aids.
glycidyl methacrylate 5 Q vt%, methyl acrylate i o vttsl butyl methacrylate)
A copolymer aqueous dispersion obtained by diluting 40 vt% of a copolymer consisting of three types of monomers to a concentration of 10 vt9J was coated on a polyethylene terephthalate film base without subbing. This emulsion was coated uniformly on both sides and dried to obtain a sensitometric sample.
次に、I−1〜I−3の試料に対しては、小西六写真工
業製の螢光スクリーンNS(レギュラータイプ用)t−
用い、I−4〜I−6の試料に対しては、同社製の螢光
スクリーンKS(オルソタイプ用)を用いて、管電圧9
0 KV 、 管電流50mAでアルミウェッジを通
しX線照射した。その後、小西六写真工業製QX−12
00自動現像機を用い、XD−90現像処理液で、90
秒処理を行いセンシトメトリーカーブを得た。その結果
は表−3に示す。Next, for samples I-1 to I-3, a fluorescent screen NS (regular type) manufactured by Konishi Roku Photo Industry was used.
For samples I-4 to I-6, a fluorescent screen KS (for orthotype) manufactured by the same company was used, and a tube voltage of 9
X-rays were irradiated through an aluminum wedge at 0 KV and a tube current of 50 mA. After that, Konishiroku Photo Industry QX-12
Using a 00 automatic developing machine, using XD-90 processing solution, 90
Second processing was performed to obtain a sensitometric curve. The results are shown in Table-3.
露光ラチチュードは、それぞれの光学濃度間の露光量差
(対数表示)で表わした。Exposure latitude was expressed as the difference in exposure amount (logarithm representation) between the respective optical densities.
この場合処理条件は前ぼの条件であシ、現像液も、前述
の現像液−1を用いた。これは上記自動現像機や現像処
理液を使用する場合の条件である。In this case, the processing conditions were as described above, and the developer used was the developer-1 described above. This is a condition when using the above-mentioned automatic processor or developing processing solution.
但し、処理時間は±2秒程度、処理温度は±IC程度の
範囲があってもよく、現像主薬であるハイドロΦノンの
量もXt中±if程度の範囲があってもよい。However, the processing time may be in the range of about ±2 seconds, the processing temperature may be in the range of about ±IC, and the amount of hydroΦnon, which is a developing agent, may be in the range of about ±if in Xt.
実施例2 実施例工と同じ試料にりいて、鮮鋭性の評価を試みた。Example 2 An attempt was made to evaluate sharpness using the same sample as in the example.
なお鮮鋭度の評価はMTF曲線の10゜1.5 、2.
011no/mの値で表わした。MTF’の測定は0.
8〜1011nes/瓢の鉛製の矩形波の入ったMTF
測定用チャートを螢光スクリーンのフロント側の裏面に
密着させ、試料面の、鉛の矩形波で遮蔽されていない部
分の濃度(つまシ背景濃度)が両面で1.0になるよう
に照射した。The sharpness was evaluated based on the MTF curve at 10°1.5, 2.
It was expressed as a value of 0.011 no/m. The measurement of MTF' is 0.
8~1011nes/MTF with square wave made of gourd lead
The measurement chart was placed in close contact with the back side of the front side of the fluorescent screen, and the sample surface was irradiated so that the density (background density) of the part not shielded by the lead square wave was 1.0 on both sides. .
その後、実施例1と同様の現像処理を行った。Thereafter, the same development treatment as in Example 1 was performed.
得られた試料の矩形波のパターンをサクシ・マイ゛クロ
デンシトメーターM−5型(小西六写真工業(株)製→
を用いて、矩形波と直角方向にスキャンニング測定した
。なお、この時のアパーチャーサイズは矩形波の平行方
向に230/Jm、直角方向に25μmで拡大倍率は1
00倍である。The square wave pattern of the obtained sample was measured using a Sakshi Microdensitometer Model M-5 (manufactured by Konishiroku Photo Industry Co., Ltd.).
Scanning measurements were performed in a direction perpendicular to the rectangular wave. The aperture size at this time is 230/Jm in the parallel direction of the rectangular wave, 25 μm in the perpendicular direction, and the magnification is 1.
00 times.
この結果は表−3に示す。The results are shown in Table-3.
実施例3
実施例1と同じ試料を、約2時間、23℃相対温度35
%の恒温、恒温に保ち、その条件下で曲率半径2信で約
2800折りまげ、圧力減感の測定を行った。Example 3 The same sample as in Example 1 was heated to 23°C relative temperature 35°C for about 2 hours.
% and was maintained at a constant temperature, and under these conditions, it was folded approximately 2,800 times with a radius of curvature of 2, and the pressure desensitization was measured.
試料は、折りまげて3分後に、アルミウェッジを用いて
管電圧80 KV 、管電流100 mAの条件下でX
線を0.06 sec照射し、実施例1と同様の現像処
理を行った。Three minutes after folding, the sample was exposed to X using an aluminum wedge under the conditions of a tube voltage of 80 KV and a tube current of 100 mA.
A line was irradiated for 0.06 sec, and the same development process as in Example 1 was performed.
得られた試料の圧力減感の度合いを、目視によって評価
した。また、この試料を用い、粒状性、及び、高PHs
高温での迅速処理によって生じる画質の劣化性も目視に
よって評価した。The degree of pressure desensitization of the obtained sample was visually evaluated. In addition, using this sample, graininess and high PHs
Deterioration of image quality caused by rapid processing at high temperatures was also visually evaluated.
ここで圧力による減感性能、粒状性及び、迅速処理によ
って生じる画質性の目視評価はその度合いの良いものか
ら5段階で表わし、lが最も良好で、数が増える程悪く
なるものとした。Here, visual evaluation of desensitization performance due to pressure, graininess, and image quality caused by rapid processing was expressed on a five-point scale from best to worst, with 1 being the best, and the higher the number, the worse it was.
これら結果も表−3に示す。These results are also shown in Table-3.
表−3かられかるように、本発明の条件を満たす試料A
l−4〜I−6は鮮鋭度も高く、かつ低濃度および高濃
度部の露光ラチチュードも広く、かつ、圧力減感も少な
いことがわかった。また、これらの試料は粒状性及び、
高p■、高温迅速処理による画質の劣化も少ないことが
わかった。As seen from Table 3, sample A that satisfies the conditions of the present invention
It was found that 1-4 to 1-6 had high sharpness, wide exposure latitude in low density and high density areas, and little pressure desensitization. In addition, these samples have granularity and
It was found that there was little deterioration in image quality due to high p■ and high temperature rapid processing.
このように、本発明の実施例に該当する試料によれば、
前記した目的を達成した、良好な結果が得られる。As described above, according to the sample corresponding to the example of the present invention,
Good results are obtained which achieve the above objectives.
上述の如く、本発明のX線感材は、高鮮鋭度で、かつ低
濃度部及び高濃度部の露光ラチチュードが広く、よって
医療用に用いる場合には診断能を高めることができ、し
かも粒状性が良く、圧力減感もしKくく、画質の劣化も
少ないという効果を有する。As described above, the X-ray sensitive material of the present invention has high sharpness and wide exposure latitude in low density areas and high density areas, and therefore can improve diagnostic performance when used for medical purposes. It has the effects of good performance, low pressure desensitization, and little deterioration in image quality.
第1図は直接用X線感材の高ガンi型(a)、低ガンi
型争)及び中庸m<c>の特性曲線を示す図である。
% zQta 9RnqtqJ、ie*量−b(”?
−’/ j ;1ミ ’fl!]?−J+:!。
第1図
Re1.LO(]”Figure 1 shows direct X-ray sensitive materials of high-gamma type i (a) and low-gamma i type (a).
FIG. % zQta 9RnqtqJ, ie*amount-b(”?
-'/j;1mi'fl! ]? -J+:! . Figure 1 Re1. LO(]”
Claims (1)
位長の等しい直角座標系上の特性曲線に於て、光学濃度
0.05の点と同0.30の点の作るガンマ(γ_1)
が0.36〜0.65であり、かつ光学濃度0.500
点と同1.50の点の作るガンマ(γ_2)が2.7〜
3.3であり、かつ光学濃度2.00と同3.00との
間のガンマ(γ_3)が1.5〜2.5であることを特
徴とするX線用ハロゲン化銀写真感光材料。 2、上記ハロゲン化銀写真感光材料は、下記一般式〔
I 〕〔II〕及び〔III〕で表わされる化合物群から選ば
れた少なくとも1種の化合物を含有する乳剤層を少なく
とも1層有することを特徴とする特許請求の範囲第1項
記載のX線用ハロゲン化銀写真感光材料。 一般式 〔 I 〕▲数式、化学式、表等があります▼ 〔式中、R_1、R_2、R_3は各々置換もしくは非
置換のアルキル基、アルケニル基またはアリール基を表
わし、少なくともR_1とR_3の内1つはスルホアル
キル基またはカルボキシ・アルキル基をとる。X^−_
1はアニオン、Z_1およびZ_2は置換または非置換
のベンゼン環を完成するに必要な非金属原子群、nは1
または2を表わす。(ただし、分子内塩を形成するとき
はnは1である。)〕 〔II〕▲数式、化学式、表等があります▼ 〔式中、R_4、R_5は各々置換もしくは非置換のア
ルキル基、アルケニル基またはアリール基を表わし、少
なくともR_4とR_5の内いずれかはスルホアルキル
基またはカルボキシアルキル基をとる。R_6は水素原
子、低級アルキル基、アリール基を表わす。 X^−_2はアニオン、Z_1およびZ_2は置換また
は非置換のベンゼン環を完成するに必要な非金属原子群
、nは1または2を表わす。(ただし、分子内塩を形成
するときはnは1である。)〕 〔III〕▲数式、化学式、表等があります▼ 〔式中、R_7およびR_9は各々置換もしくは非置換
の低級アルキル基、R_8およびR_1_0は低級アル
キル基、ヒドロキシアルキル基、スルホアルキル基、カ
ルボキシアルキル基、X^−_3はアニオン、Z_1お
よびZ_2は置換または非置換のベンゼン環を完成する
に必要な非金属原子群、nは1または2を表わす。 (ただし、分子内塩を形成するときはnは1である。)
〕[Claims] 1. In a characteristic curve on a rectangular coordinate system with the same unit length of the coordinate axes of optical density (D) and exposure dose (logE), a point with an optical density of 0.05 and a point with the same unit length of 0.30. Gamma (γ_1) created by
is 0.36 to 0.65, and optical density is 0.500
The gamma (γ_2) created by the point with the same 1.50 as the point is 2.7 ~
3.3, and has a gamma (γ_3) between 2.00 and 3.00 of optical density of 1.5 to 2.5. 2. The above silver halide photographic material has the following general formula [
I ] [II] and [III] The X-ray device according to claim 1, characterized in that it has at least one emulsion layer containing at least one compound selected from the compound group represented by [II] and [III]. Silver halide photographic material. General formula [I] ▲ Numerical formulas, chemical formulas, tables, etc. takes a sulfoalkyl group or a carboxyalkyl group. X^−_
1 is an anion, Z_1 and Z_2 are nonmetallic atomic groups necessary to complete the substituted or unsubstituted benzene ring, n is 1
or 2. (However, when forming an inner salt, n is 1.) [II] ▲ Numerical formulas, chemical formulas, tables, etc. ▼ [In the formula, R_4 and R_5 are substituted or unsubstituted alkyl groups, alkenyl or aryl group, and at least one of R_4 and R_5 is a sulfoalkyl group or a carboxyalkyl group. R_6 represents a hydrogen atom, a lower alkyl group, or an aryl group. X^-_2 represents an anion, Z_1 and Z_2 represent a group of nonmetallic atoms necessary to complete a substituted or unsubstituted benzene ring, and n represents 1 or 2. (However, when forming an inner salt, n is 1.) [III] ▲ Numerical formulas, chemical formulas, tables, etc. ▼ [In the formula, R_7 and R_9 are each substituted or unsubstituted lower alkyl group, R_8 and R_1_0 are lower alkyl groups, hydroxyalkyl groups, sulfoalkyl groups, carboxyalkyl groups, X^-_3 is an anion, Z_1 and Z_2 are nonmetallic atomic groups necessary to complete the substituted or unsubstituted benzene ring, n represents 1 or 2. (However, when forming an inner salt, n is 1.)
]
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23713484A JPS61116346A (en) | 1984-11-11 | 1984-11-11 | Silver halide photosensitive material |
US06/794,641 US4689292A (en) | 1984-11-11 | 1985-11-04 | Silver halide photographic radiography light-sensitive material |
DE19853539930 DE3539930A1 (en) | 1984-11-11 | 1985-11-11 | LIGHT SENSITIVE PHOTOGRAPHIC SILVER HALOGENID MATERIAL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23713484A JPS61116346A (en) | 1984-11-11 | 1984-11-11 | Silver halide photosensitive material |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61116346A true JPS61116346A (en) | 1986-06-03 |
JPH053568B2 JPH053568B2 (en) | 1993-01-18 |
Family
ID=17010907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP23713484A Granted JPS61116346A (en) | 1984-11-11 | 1984-11-11 | Silver halide photosensitive material |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61116346A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6242147A (en) * | 1985-08-20 | 1987-02-24 | Konishiroku Photo Ind Co Ltd | Silver halide photographic sensitive material for x-rays |
JPS63101840A (en) * | 1986-10-18 | 1988-05-06 | Konica Corp | Radiographic image forming method using radiographic film having high shelf stability |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59116648A (en) * | 1982-12-13 | 1984-07-05 | Konishiroku Photo Ind Co Ltd | Silver halide photosensitive material |
JPS59116647A (en) * | 1982-12-13 | 1984-07-05 | Konishiroku Photo Ind Co Ltd | Silver halide photosensitive material |
-
1984
- 1984-11-11 JP JP23713484A patent/JPS61116346A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59116648A (en) * | 1982-12-13 | 1984-07-05 | Konishiroku Photo Ind Co Ltd | Silver halide photosensitive material |
JPS59116647A (en) * | 1982-12-13 | 1984-07-05 | Konishiroku Photo Ind Co Ltd | Silver halide photosensitive material |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6242147A (en) * | 1985-08-20 | 1987-02-24 | Konishiroku Photo Ind Co Ltd | Silver halide photographic sensitive material for x-rays |
JPS63101840A (en) * | 1986-10-18 | 1988-05-06 | Konica Corp | Radiographic image forming method using radiographic film having high shelf stability |
Also Published As
Publication number | Publication date |
---|---|
JPH053568B2 (en) | 1993-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2110402A (en) | Radiographic element | |
EP0126644B1 (en) | Light-sensitive silver halide photographic material for x-ray photography | |
GB2127986A (en) | Radiographic element | |
JPS6180237A (en) | Photosensitive silver halide emulsion | |
JPS6324238A (en) | Photosensitive silver halide emulsion and radiation photographic element with improved image quality and reduced contamination | |
US4689292A (en) | Silver halide photographic radiography light-sensitive material | |
JPS59178447A (en) | Silver halide emulsion layer | |
JPH0514887B2 (en) | ||
JPS61116346A (en) | Silver halide photosensitive material | |
JPH10301217A (en) | Photographic silver halide material for mammography | |
US5206132A (en) | Direct positive silver halide photographic light-sensitive material | |
JPH0223855B2 (en) | ||
JPH0315728B2 (en) | ||
JP3557808B2 (en) | Silver halide photographic emulsion, method for producing the same, silver halide photographic light-sensitive material and processing method | |
JPH0314328B2 (en) | ||
JPS62229131A (en) | Silver halide photographic sensitive material for x ray use | |
JPH0522903B2 (en) | ||
JP2683736B2 (en) | High-speed processing silver halide photographic light-sensitive material with improved sharpness and less residual color | |
JPH0576021B2 (en) | ||
JP2821504B2 (en) | Silver halide photographic material | |
JPH0514888B2 (en) | ||
JPS62174739A (en) | Silver halide photographic sensitive material for x-ray | |
JP806H (en) | Silver halide photographic material for X-ray | |
JPH0621917B2 (en) | Silver halide photographic material for X-ray | |
JPH068945B2 (en) | Silver halide photographic light-sensitive material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |